0 XP   0   0   0

GlaxoSmithKline Pharmaceuticals Limited
Buy, Hold or Sell?

Should you buy, hold or sell GlaxoSmithKline Pharmaceuticals Limited?

I guess you are interested in GlaxoSmithKline Pharmaceuticals Limited. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's analyse GlaxoSmithKline Pharmaceuticals Limited

Let's start. I'm going to help you getting a better view of GlaxoSmithKline Pharmaceuticals Limited. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

  1. Company's Financial Health
    A deep dive into the books. How are the numbers doing? Is GlaxoSmithKline Pharmaceuticals Limited even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
  2. Market Valuation
    Finally, you now have an insight of how GlaxoSmithKline Pharmaceuticals Limited is doing in the market. If the company is worth buying. The latest step is to find out how other investors value GlaxoSmithKline Pharmaceuticals Limited. The closing price on 2023-01-27 was INR1,262 per share. Is the company over- or underpriced?
  3. Key Performance Indicators
    A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.
GlaxoSmithKline Pharmaceuticals Limited Daily Candlestick Chart
GlaxoSmithKline Pharmaceuticals Limited Daily Candlestick Chart
Summary









1. Valuation of GlaxoSmithKline Pharmaceuticals Limited




Current price per share

INR1,261.60

2. Growth of GlaxoSmithKline Pharmaceuticals Limited




Is GlaxoSmithKline Pharmaceuticals Limited growing?

Current yearPrevious yearGrowGrow %
How rich?$327.5m$181.8m$145.7m44.5%

How much money is GlaxoSmithKline Pharmaceuticals Limited making?

Current yearPrevious yearGrowGrow %
Making money$208.4m$44m$164.3m78.9%
Net Profit Margin51.7%12.2%--

How much money comes from the company's main activities?

3. Financial Health of GlaxoSmithKline Pharmaceuticals Limited




Comparing to competitors in the Pharmaceuticals industry




  Industry Rankings (Pharmaceuticals)  


Richest
#17 / 54

Most Revenue
#14 / 54


Summary

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is very efficient in making profit.
Using its investors money, the company is very efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

1.1. Profitability of GlaxoSmithKline Pharmaceuticals Limited.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit GlaxoSmithKline Pharmaceuticals Limited earns for each ₹1 of revenue.

  • Above 10% is considered healthy but always compare GlaxoSmithKline Pharmaceuticals Limited to the Pharmaceuticals industry mean.
  • A Net Profit Margin of 51.7% means that ₹0.52 for each ₹1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of GlaxoSmithKline Pharmaceuticals Limited:

  • The MRQ is 51.7%. The company is making a huge profit. +2
  • The TTM is 51.7%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ51.7%TTM51.7%0.0%
TTM51.7%YOY12.2%+39.5%
TTM51.7%5Y18.6%+33.1%
5Y18.6%10Y16.8%+1.8%
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ51.7%3.3%+48.4%
TTM51.7%6.9%+44.8%
YOY12.2%9.9%+2.3%
5Y18.6%6.3%+12.3%
10Y16.8%6.7%+10.1%
1.1.2. Return on Assets

Shows how efficient GlaxoSmithKline Pharmaceuticals Limited is using its assets to generate profit.

  • Above 5% is considered healthy but always compare GlaxoSmithKline Pharmaceuticals Limited to the Pharmaceuticals industry mean.
  • 36.6% Return on Assets means that GlaxoSmithKline Pharmaceuticals Limited generated ₹0.37 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of GlaxoSmithKline Pharmaceuticals Limited:

  • The MRQ is 36.6%. Using its assets, the company is very efficient in making profit. +2
  • The TTM is 36.6%. Using its assets, the company is very efficient in making profit. +2
Trends
Current periodCompared to+/- 
MRQ36.6%TTM36.6%0.0%
TTM36.6%YOY11.5%+25.1%
TTM36.6%5Y14.3%+22.3%
5Y14.3%10Y13.5%+0.7%
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ36.6%0.8%+35.8%
TTM36.6%1.3%+35.3%
YOY11.5%1.5%+10.0%
5Y14.3%1.4%+12.9%
10Y13.5%1.4%+12.1%
1.1.3. Return on Equity

Shows how efficient GlaxoSmithKline Pharmaceuticals Limited is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare GlaxoSmithKline Pharmaceuticals Limited to the Pharmaceuticals industry mean.
  • 63.6% Return on Equity means GlaxoSmithKline Pharmaceuticals Limited generated ₹0.64 for each ₹1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of GlaxoSmithKline Pharmaceuticals Limited:

  • The MRQ is 63.6%. Using its investors money, the company is very efficient in making profit. +2
  • The TTM is 63.6%. Using its investors money, the company is very efficient in making profit. +2
Trends
Current periodCompared to+/- 
MRQ63.6%TTM63.6%0.0%
TTM63.6%YOY24.2%+39.4%
TTM63.6%5Y26.2%+37.5%
5Y26.2%10Y23.6%+2.6%
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ63.6%1.5%+62.1%
TTM63.6%2.0%+61.6%
YOY24.2%3.0%+21.2%
5Y26.2%2.1%+24.1%
10Y23.6%2.0%+21.6%

1.2. Operating Efficiency of GlaxoSmithKline Pharmaceuticals Limited.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient GlaxoSmithKline Pharmaceuticals Limited is operating .

  • Measures how much profit GlaxoSmithKline Pharmaceuticals Limited makes for each ₹1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare GlaxoSmithKline Pharmaceuticals Limited to the Pharmaceuticals industry mean.
  • An Operating Margin of 0.0% means the company generated ₹0.00  for each ₹1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of GlaxoSmithKline Pharmaceuticals Limited:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y11.1%-11.1%
5Y11.1%10Y10.5%+0.6%
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ--5.6%+5.6%
TTM-0.5%-0.5%
YOY-6.2%-6.2%
5Y11.1%5.1%+6.0%
10Y10.5%5.2%+5.3%
1.2.2. Operating Ratio

Measures how efficient GlaxoSmithKline Pharmaceuticals Limited is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Pharmaceuticals industry mean).
  • An Operation Ratio of 1.24 means that the operating costs are ₹1.24 for each ₹1 in net sales.

Let's take a look of the Operating Ratio trends of GlaxoSmithKline Pharmaceuticals Limited:

  • The MRQ is 1.239. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.239. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.239TTM1.2390.000
TTM1.239YOY1.339-0.100
TTM1.2395Y1.295-0.056
5Y1.29510Y1.194+0.101
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2391.342-0.103
TTM1.2391.276-0.037
YOY1.3391.169+0.170
5Y1.2951.149+0.146
10Y1.1941.178+0.016

1.3. Liquidity of GlaxoSmithKline Pharmaceuticals Limited.

1.3. Liquidity
1.3.1. Current Ratio

Measures if GlaxoSmithKline Pharmaceuticals Limited is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Pharmaceuticals industry mean).
  • A Current Ratio of 2.18 means the company has ₹2.18 in assets for each ₹1 in short-term debts.

Let's take a look of the Current Ratio trends of GlaxoSmithKline Pharmaceuticals Limited:

  • The MRQ is 2.183. The company is able to pay all its short-term debts. +1
  • The TTM is 2.183. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.183TTM2.1830.000
TTM2.183YOY1.626+0.557
TTM2.1835Y1.658+0.525
5Y1.65810Y2.053-0.394
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ2.1832.205-0.022
TTM2.1832.010+0.173
YOY1.6262.125-0.499
5Y1.6581.812-0.154
10Y2.0531.786+0.267
1.3.2. Quick Ratio

Measures if GlaxoSmithKline Pharmaceuticals Limited is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare GlaxoSmithKline Pharmaceuticals Limited to the Pharmaceuticals industry mean.
  • A Quick Ratio of 3.29 means the company can pay off ₹3.29 for each ₹1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of GlaxoSmithKline Pharmaceuticals Limited:

  • The MRQ is 3.286. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.286. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.286TTM3.2860.000
TTM3.286YOY1.539+1.747
TTM3.2865Y2.008+1.278
5Y2.00810Y2.169-0.161
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ3.2861.118+2.168
TTM3.2861.152+2.134
YOY1.5391.091+0.448
5Y2.0081.007+1.001
10Y2.1690.869+1.300

1.4. Solvency of GlaxoSmithKline Pharmaceuticals Limited.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of GlaxoSmithKline Pharmaceuticals Limited assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare GlaxoSmithKline Pharmaceuticals Limited to Pharmaceuticals industry mean.
  • A Debt to Asset Ratio of 0.43 means that GlaxoSmithKline Pharmaceuticals Limited assets are financed with 42.5% credit (debt) and the remaining percentage (100% - 42.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of GlaxoSmithKline Pharmaceuticals Limited:

  • The MRQ is 0.425. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.425. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.425TTM0.4250.000
TTM0.425YOY0.525-0.100
TTM0.4255Y0.460-0.035
5Y0.46010Y0.417+0.043
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4250.381+0.044
TTM0.4250.379+0.046
YOY0.5250.417+0.108
5Y0.4600.398+0.062
10Y0.4170.399+0.018
1.4.2. Debt to Equity Ratio

Measures if GlaxoSmithKline Pharmaceuticals Limited is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare GlaxoSmithKline Pharmaceuticals Limited to the Pharmaceuticals industry mean.
  • A Debt to Equity ratio of 74.0% means that company has ₹0.74 debt for each ₹1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of GlaxoSmithKline Pharmaceuticals Limited:

  • The MRQ is 0.740. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.740. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.740TTM0.7400.000
TTM0.740YOY1.107-0.367
TTM0.7405Y0.863-0.123
5Y0.86310Y0.745+0.119
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7400.586+0.154
TTM0.7400.598+0.142
YOY1.1070.598+0.509
5Y0.8630.671+0.192
10Y0.7450.664+0.081

2. Market Valuation of GlaxoSmithKline Pharmaceuticals Limited

2. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₹1 in earnings GlaxoSmithKline Pharmaceuticals Limited generates.

  • Above 15 is considered overpriced but always compare GlaxoSmithKline Pharmaceuticals Limited to the Pharmaceuticals industry mean.
  • A PE ratio of 17.60 means the investor is paying ₹17.60 for every ₹1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of GlaxoSmithKline Pharmaceuticals Limited:

  • The EOD is 12.611. Very good. +2
  • The MRQ is 17.598. Very good. +2
  • The TTM is 17.598. Very good. +2
Trends
Current periodCompared to+/- 
EOD12.611MRQ17.598-4.987
MRQ17.598TTM17.5980.000
TTM17.598YOY76.778-59.180
TTM17.5985Y112.804-95.206
5Y112.80410Y100.193+12.612
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
EOD12.61140.785-28.174
MRQ17.59851.661-34.063
TTM17.59851.419-33.821
YOY76.77864.495+12.283
5Y112.80456.903+55.901
10Y100.19361.712+38.481
2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of GlaxoSmithKline Pharmaceuticals Limited.

  • Lower is better.
  • A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of GlaxoSmithKline Pharmaceuticals Limited:

  • The MRQ is 3.719. Seems overpriced? -1
  • The TTM is 3.719. Seems overpriced? -1
Trends
Current periodCompared to+/- 
MRQ3.719TTM3.7190.000
TTM3.719YOY19.981-16.262
TTM3.7195Y316.190-312.471
5Y316.19010Y316.1900.000
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ3.7190.015+3.704
TTM3.7190.036+3.683
YOY19.9810.327+19.654
5Y316.1900.144+316.046
10Y316.1900.144+316.046

2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of GlaxoSmithKline Pharmaceuticals Limited is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Pharmaceuticals industry mean).
  • A PB ratio of 11.20 means the investor is paying ₹11.20 for each ₹1 in book value.

Let's take a look of the Price to Book Ratio trends of GlaxoSmithKline Pharmaceuticals Limited:

  • The EOD is 8.026. Seems overpriced? -1
  • The MRQ is 11.200. Seems overpriced? -1
  • The TTM is 11.200. Seems overpriced? -1
Trends
Current periodCompared to+/- 
EOD8.026MRQ11.200-3.174
MRQ11.200TTM11.2000.000
TTM11.200YOY18.602-7.402
TTM11.2005Y15.432-4.233
5Y15.43210Y14.316+1.117
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
EOD8.0262.248+5.778
MRQ11.2002.690+8.510
TTM11.2003.050+8.150
YOY18.6023.185+15.417
5Y15.4322.899+12.533
10Y14.3162.711+11.605
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of GlaxoSmithKline Pharmaceuticals Limited compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--69.93269.9320%-20.209+129%7.746+803%26.199+167%
Book Value Growth--1.8011.8010%0.812+122%1.106+63%1.075+68%
Book Value Per Share--157.194157.1940%87.261+80%119.936+31%102.592+53%
Book Value Per Share Growth--1.8011.8010%0.812+122%1.106+63%1.106+63%
Current Ratio--2.1832.1830%1.626+34%1.658+32%2.053+6%
Debt To Asset Ratio--0.4250.4250%0.525-19%0.460-8%0.417+2%
Debt To Equity Ratio--0.7400.7400%1.107-33%0.863-14%0.745-1%
Dividend Per Share--29.90729.9070%40.000-25%24.481+22%24.568+22%
Dividend Per Share Growth--0.7480.7480%2.000-63%1.131-34%1.131-34%
Eps--100.039100.0390%21.141+373%34.735+188%27.651+262%
Eps Growth--4.7324.7320%3.843+23%2.219+113%2.219+113%
Free Cash Flow Per Share--45.81345.8130%31.504+45%21.509+113%17.251+166%
Free Cash Flow Per Share Growth--1.4541.4540%1.595-9%2.143-32%2.143-32%
Free Cash Flow To Equity Per Share--14.86814.8680%-9.589+164%-5.798+139%-10.530+171%
Free Cash Flow To Equity Per Share Growth--3.5513.5510%0.254+1299%1.594+123%1.594+123%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--1219.161--------
Intrinsic Value_10Y_min--1020.040--------
Intrinsic Value_1Y_max--62.415--------
Intrinsic Value_1Y_min--60.649--------
Intrinsic Value_3Y_max--233.071--------
Intrinsic Value_3Y_min--219.306--------
Intrinsic Value_5Y_max--458.631--------
Intrinsic Value_5Y_min--417.387--------
Net Profit Margin--0.5170.5170%0.122+322%0.186+177%0.168+208%
Operating Margin----0%-0%0.111-100%0.105-100%
Operating Ratio--1.2391.2390%1.339-7%1.295-4%1.194+4%
Pb Ratio8.026-40%11.20011.2000%18.602-40%15.432-27%14.316-22%
Pe Ratio12.611-40%17.59817.5980%76.778-77%112.804-84%100.193-82%
Peg Ratio--3.7193.7190%19.981-81%316.190-99%316.190-99%
Price Per Share1261.600-40%1760.5001760.5000%1623.200+8%1796.900-2%2147.986-18%
Price To Total Gains Ratio12.636-40%17.63317.6330%82.015-78%339.231-95%285.864-94%
Profit Growth--4.7324.7320%3.843+23%2.219+113%1.998+137%
Quick Ratio--3.2863.2860%1.539+113%2.008+64%2.169+51%
Return On Assets--0.3660.3660%0.115+218%0.143+156%0.135+170%
Return On Equity--0.6360.6360%0.242+163%0.262+143%0.236+170%
Revenue Growth--1.1201.1200%0.907+23%1.021+10%1.027+9%
Total Gains Per Share--99.83999.8390%19.791+404%32.227+210%50.767+97%
Total Gains Per Share Growth--5.0455.0450%17.117-71%4.716+7%4.716+7%
Usd Book Value--327543563.400327543563.4000%181825967.700+80%249910876.020+31%252133878.214+30%
Usd Book Value Change Per Share--0.8600.8600%-0.249+129%0.095+803%0.322+167%
Usd Book Value Per Share--1.9331.9330%1.073+80%1.475+31%1.262+53%
Usd Dividend Per Share--0.3680.3680%0.492-25%0.301+22%0.302+22%
Usd Eps--1.2301.2300%0.260+373%0.427+188%0.340+262%
Usd Free Cash Flow--95461136.40095461136.4000%65645100.000+45%44819172.960+113%32013694.971+198%
Usd Free Cash Flow Per Share--0.5640.5640%0.388+45%0.265+113%0.212+166%
Usd Free Cash Flow To Equity Per Share--0.1830.1830%-0.118+164%-0.071+139%-0.130+171%
Usd Price Per Share15.518-40%21.65421.6540%19.965+8%22.102-2%26.420-18%
Usd Profit--208450473.900208450473.9000%44052117.900+373%72377874.000+188%64226059.543+225%
Usd Revenue--403197591.600403197591.6000%359849009.100+12%380113743.720+6%374090056.286+8%
Usd Total Gains Per Share--1.2281.2280%0.243+404%0.396+210%0.624+97%
 EOD+3 -2MRQTTM+0 -0YOY+34 -75Y+37 -510Y+35 -7

3.2. Fundamental Score

Let's check the fundamental score of GlaxoSmithKline Pharmaceuticals Limited based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1512.611
Price to Book Ratio (EOD)Between0-18.026
Net Profit Margin (MRQ)Greater than00.517
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than13.286
Current Ratio (MRQ)Greater than12.183
Debt to Asset Ratio (MRQ)Less than10.425
Debt to Equity Ratio (MRQ)Less than10.740
Return on Equity (MRQ)Greater than0.150.636
Return on Assets (MRQ)Greater than0.050.366
Total8/10 (80.0%)

3.3. Technical Score

Let's check the technical score of GlaxoSmithKline Pharmaceuticals Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose1,265.000
Total1/1 (100.0%)



Latest Balance Sheet

Balance Sheet of 2021-12-31. Currency in INR. All numbers in thousands.

Summary
Total Assets46,332,778
Total Liabilities19,703,220
Total Stockholder Equity26,629,558
 As reported
Total Liabilities 19,703,220
Total Stockholder Equity+ 26,629,558
Total Assets = 46,332,778

Assets

Total Assets46,332,778
Total Current Assets37,080,323
Long-term Assets37,080,323
Total Current Assets
Cash And Cash Equivalents 561,271
Short-term Investments 25,446,923
Net Receivables 2,052,389
Inventory 5,346,954
Other Current Assets 233,666
Total Current Assets  (as reported)37,080,323
Total Current Assets  (calculated)33,641,203
+/- 3,439,120
Long-term Assets
Property Plant Equipment 3,254,472
Intangible Assets 344,974
Other Assets 1,255,428
Long-term Assets  (as reported)9,252,247
Long-term Assets  (calculated)4,854,874
+/- 4,397,373

Liabilities & Shareholders' Equity

Total Current Liabilities16,984,288
Long-term Liabilities2,718,932
Total Stockholder Equity26,629,558
Total Current Liabilities
Accounts payable 5,705,487
Other Current Liabilities 1,292
Total Current Liabilities  (as reported)16,984,288
Total Current Liabilities  (calculated)5,706,779
+/- 11,277,509
Long-term Liabilities
Long term Debt Total 76,235
Capital Lease Obligations Min Short Term Debt200,765
Long-term Liabilities  (as reported)2,718,932
Long-term Liabilities  (calculated)277,000
+/- 2,441,932
Total Stockholder Equity
Common Stock1,694,060
Retained Earnings 24,935,498
Total Stockholder Equity (as reported)26,629,558
Total Stockholder Equity (calculated)26,629,558
+/-0
Other
Capital Stock1,694,060
Cash And Equivalents2,300,600
Cash and Short Term Investments 28,308,794
Common Stock Shares Outstanding 169,406
Liabilities and Stockholders Equity 46,332,778
Net Invested Capital 26,629,558
Net Working Capital 20,096,035



Balance Sheet

Currency in INR. All numbers in thousands.

 Trend2021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-31
> Total Assets 
30,548,849
30,038,353
39,474,827
39,113,109
31,355,410
31,146,474
46,332,778
46,332,77831,146,47431,355,41039,113,10939,474,82730,038,35330,548,849
   > Total Current Assets 
21,737,270
16,742,459
21,864,082
20,094,620
17,748,814
22,026,398
37,080,323
37,080,32322,026,39817,748,81420,094,62021,864,08216,742,45921,737,270
       Cash And Cash Equivalents 
562,336
1,068,622
1,100,100
300,300
60,000
2,061,192
561,271
561,2712,061,19260,000300,3001,100,1001,068,622562,336
       Short-term Investments 
0
7,672,460
10,690,145
10,490,145
9,570,145
7,320,000
25,446,923
25,446,9237,320,0009,570,14510,490,14510,690,1457,672,4600
       Net Receivables 
1,265,650
1,707,967
1,469,589
1,204,873
998,012
2,156,046
2,052,389
2,052,3892,156,046998,0121,204,8731,469,5891,707,9671,265,650
       Inventory 
5,258,666
4,257,974
5,001,833
4,864,935
4,830,322
5,466,981
5,346,954
5,346,9545,466,9814,830,3224,864,9355,001,8334,257,9745,258,666
       Other Current Assets 
882,363
894,389
1,639,395
352,065
276,371
2,066,161
233,666
233,6662,066,161276,371352,0651,639,395894,389882,363
   > Long-term Assets 
0
13,312,189
17,660,119
19,051,760
13,606,596
9,107,000
9,252,247
9,252,2479,107,00013,606,59619,051,76017,660,11913,312,1890
       Property Plant Equipment 
4,717,116
8,259,263
11,730,238
13,670,968
8,270,867
3,554,107
3,254,472
3,254,4723,554,1078,270,86713,670,96811,730,2388,259,2634,717,116
       Intangible Assets 
0
322,473
726,818
655,400
496,251
433,640
344,974
344,974433,640496,251655,400726,818322,4730
       Long-term Assets Other 
0
306,098
408,414
322,761
149,203
501,700
13,318
13,318501,700149,203322,761408,414306,0980
> Total Liabilities 
8,716,369
9,969,795
18,901,538
17,714,817
13,149,361
16,363,875
19,703,220
19,703,22016,363,87513,149,36117,714,81718,901,5389,969,7958,716,369
   > Total Current Liabilities 
5,792,107
7,202,325
15,998,637
14,543,195
10,242,572
13,545,807
16,984,288
16,984,28813,545,80710,242,57214,543,19515,998,6377,202,3255,792,107
       Short-term Debt 
0
0
0
0
0
240
0
024000000
       Short Long Term Debt 
0
6,060
4,060
4,060
1,530
240
0
02401,5304,0604,0606,0600
       Accounts payable 
0
5,224,802
6,462,468
4,825,341
3,575,851
4,644,700
5,705,487
5,705,4874,644,7003,575,8514,825,3416,462,4685,224,8020
       Other Current Liabilities 
0
312,952
199,157
150,647
651,258
2,638,500
1,292
1,2922,638,500651,258150,647199,157312,9520
   > Long-term Liabilities 
0
2,767,470
2,902,901
3,171,622
2,906,789
2,818,100
2,718,932
2,718,9322,818,1002,906,7893,171,6222,902,9012,767,4700
       Long term Debt Total 
15,950
9,890
5,830
1,770
268,612
202,499
76,235
76,235202,499268,6121,7705,8309,89015,950
> Total Stockholder Equity
21,832,480
20,068,558
20,573,289
21,398,292
18,206,049
14,782,599
26,629,558
26,629,55814,782,59918,206,04921,398,29220,573,28920,068,55821,832,480
   Common Stock
847,030
847,030
847,030
1,694,060
1,694,060
1,694,060
1,694,060
1,694,0601,694,0601,694,0601,694,060847,030847,030847,030
   Retained Earnings 
20,985,450
19,221,528
19,726,259
19,704,232
16,511,989
13,088,539
24,935,498
24,935,49813,088,53916,511,98919,704,23219,726,25919,221,52820,985,450
   Capital Surplus 0000000
   Treasury Stock0000000
   Other Stockholders Equity 0000000



Balance Sheet

Currency in INR. All numbers in thousands.




Cash Flow

Currency in INR. All numbers in thousands.




Income Statement

Currency in INR. All numbers in thousands.


Latest Income Statement (annual, 2021-12-31)

Gross Profit (+$)
totalRevenue32,780,292
Cost of Revenue-14,821,417
Gross Profit17,958,87517,958,875
 
Operating Income (+$)
Gross Profit17,958,875
Operating Expense-25,791,949
Operating Income6,790,041-7,833,074
 
Operating Expense (+$)
Research Development-
Selling General Administrative9,818,150
Selling And Marketing Expenses-
Operating Expense25,791,9499,818,150
 
Net Interest Income (+$)
Interest Income648,725
Interest Expense-1,438
Net Interest Income697,490647,287
 
Pretax Income (+$)
Operating Income6,790,041
Net Interest Income697,490
Other Non-Operating Income Expenses-
Income Before Tax (EBT)7,790,4816,790,041
EBIT - interestExpense = -1,438
16,947,193
16,948,631
Interest Expense1,438
Earnings Before Interest and Taxes (ebit)-7,791,919
Earnings Before Interest and Taxes (ebitda)8,492,302
 
After tax Income (+$)
Income Before Tax7,790,481
Tax Provision-3,982,792
Net Income From Continuing Ops3,807,6893,807,689
Net Income16,947,193
Net Income Applicable To Common Shares16,947,193
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items13,139,504
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net--697,490
 

Comments

Join the conversation.

Leave a comment

Stay informed with my latest content.

Subscribe to my newsletter and receive an email as soon as I add content to PenkeTrading.com.


By clicking Register, you agree to the General Terms and Conditions.
Penke's Market Notifications
NGU24-NYM.COMM
1 hour ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of NGU24-NYM.COMM.

NGU24-NYM.COMM Daily Candlestick Chart
NGM24-NYM.COMM
1 hour ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of NGM24-NYM.COMM.

NGM24-NYM.COMM Daily Candlestick Chart
NGQ24-NYM.COMM
1 hour ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of NGQ24-NYM.COMM.

NGQ24-NYM.COMM Daily Candlestick Chart
ISKJ.MCX
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of ISKJ.MCX.

ISKJ.MCX Daily Candlestick Chart
CHKZ.MCX
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of CHKZ.MCX.

CHKZ.MCX Daily Candlestick Chart
VSYD.MCX
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of VSYD.MCX.

VSYD.MCX Daily Candlestick Chart
VRSB.MCX
1 hour ago

I found you a Golden Cross on the daily chart of VRSB.MCX.

VRSB.MCX Daily Candlestick Chart
TBRU.MCX
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of TBRU.MCX.

TBRU.MCX Daily Candlestick Chart
SNGSP.MCX
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of SNGSP.MCX.

SNGSP.MCX Daily Candlestick Chart
RBCM.MCX
1 hour ago

I found you a Golden Cross on the daily chart of RBCM.MCX.

RBCM.MCX Daily Candlestick Chart
OKEY.MCX
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of OKEY.MCX.

OKEY.MCX Daily Candlestick Chart
MTLR.MCX
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of MTLR.MCX.

MTLR.MCX Daily Candlestick Chart
MRKZ.MCX
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of MRKZ.MCX.

MRKZ.MCX Daily Candlestick Chart
KRKN.MCX
1 hour ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of KRKN.MCX.

KRKN.MCX Daily Candlestick Chart
JNOS.MCX
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of JNOS.MCX.

JNOS.MCX Daily Candlestick Chart
BLNG.MCX
2 hours ago

I found you a Golden Cross on the daily chart of BLNG.MCX.

BLNG.MCX Daily Candlestick Chart
ASSB.MCX
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of ASSB.MCX.

ASSB.MCX Daily Candlestick Chart
CSYZ.MU
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of CSYZ.MU.

CSYZ.MU Daily Candlestick Chart
MOH.MU
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of MOH.MU.

MOH.MU Daily Candlestick Chart
TBK.V
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of TBK.V.

TBK.V Daily Candlestick Chart
UMDK.F
2 hours ago

I found you a STOCH Bullish Hidden Divergence on the daily chart of UMDK.F.

UMDK.F Daily Candlestick Chart
RY4C.BE
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of RY4C.BE.

RY4C.BE Daily Candlestick Chart
PLY.BE
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of PLY.BE.

PLY.BE Daily Candlestick Chart
PDL.LSE
2 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of PDL.LSE.

PDL.LSE Daily Candlestick Chart
27F0.MU
2 hours ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of 27F0.MU.

27F0.MU Daily Candlestick Chart